# US 2026/0137723 A1 · Deprivation of human pluripotent stem cell-derived trpv1+, mrgprx1+ and scn9a+ sensory neurons and their functional characterization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0137723 A1
- Document ID: US20260137723A1
- Status: Published application
- Kind: A1
- Application number: 19/385,524
- Filed: 2025-11-11
- Published: 2026-05-21
- Earliest claimed: 2023-11-16
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Gabsang LEE; Xinzhong DONG; Zhuolun Poppy WANG
- Web page: https://patentgrep.com/patent/US20260137723A1

## CPC

- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61P 25/02: for peripheral neuropathies
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- C07K 14/47: from mammals
- C12N 5/062: {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2501/01: Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/13: Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/42: Notch; Delta; Jagged; Serrate
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/02: from embryonic cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2510/00: Genetically modified cells
- C12N 2533/32: Polylysine, polyornithine
- C12N 2533/52: Fibronectin; Laminin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are methods of producing a population of pluripotent stem cell-derived sensory neurons (PSC-SNs) expressing a target gene associated with pain. In addition, provided herein are compositions and methods comprising populations of pluripotent stems cells for treating pain, osteoarthritis, and osteoarthritis related conditions.

## Claims

### Claim 1

An isolated population of cells comprising pluripotent stem cell-derived sensory neurons (PSC-SNs) or descendants thereof, the PSC-SNs expressing one or more of a sensory neuron marker and a pan neuronal marker.

### Claim 2 (depends on 1)

The isolated population of cells of claim 1, wherein the PSC-SNs respond to a stimulus that is nociceptive and pruriceptive.

### Claim 3 (depends on 1)

The isolated population of cells of claim 1, comprising cells that express one or more of TRPV1, SCN9A, MRGPRX1, and KCNQ2.

### Claim 4 (depends on 1)

The isolated population of cells of claim 1, comprising cells that express CD200high.

### Claim 5 (depends on 1)

The isolated population of cells of claim 1, wherein at least 40% of cells in the isolated population of cells express CD200high.

### Claim 6 (depends on 1)

The isolated population of cells of claim 1, wherein the PSC-SNs comprise PSC-SNs that are derived from a human (hPSC-SNs).

### Claim 7 (depends on 1)

The isolated population of cells of claim 1, wherein the PSC-SNs comprise pluripotent stem cell-derived nociceptive sensory neurons (PSC-NSNs).

### Claim 8

A method, comprising: administering pluripotent stem cell-derived sensory neurons (PSC-SNs) to a subject, the PSC-SNs expressing one or more of a sensory neuron marker and a pan neuronal marker.

### Claim 9 (depends on 8)

The method of claim 8, wherein the method is a method to treat pain.

### Claim 10 (depends on 8)

The method of claim 8, wherein the method is a method to treat osteoarthritis.

### Claim 11 (depends on 8)

The method of claim 8, wherein the administering comprises administering the cells to a joint of the subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein the joint is a knee joint.

### Claim 13 (depends on 8)

The method of claim 8, wherein the pain comprises one or more of chronic pain, nociceptive pain, and pruriceptive pain.

### Claim 14 (depends on 8)

The method of claim 8, wherein the method reduces expression of matrix metalloproteinase 13 (MMP13) in the subject by at least about 10%.

### Claim 15

A composition for base editing target gene mutations, comprising:
a base editor; and
a guide RNA (gRNA),
the base editor and the gRNA targeting at least one gene, the at least one gene comprising SCN9A, TRPV1, MRGPRX1, or KCNQ2.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the gRNA comprises a sequence selected from any one of SEQ ID NOs: 82-97.

### Claim 17 (depends on 15)

The composition of claim 15, wherein the gRNA comprises a spacer sequence selected from any one of SEQ ID NOs: 17, 22, 27, 32, 35, 38, 41, 44, 47, 50, 53, 56, or 59-81.

### Claim 18 (depends on 15)

The composition of claim 15, wherein the base editor comprises ABE8e, ABE8e(V106W), ABE9, ABE20, ABE7.10, SaKKHABE8e, SauriCas9-ABE8e, CjCas9-ABE8e, Nme2Cas9-ABE8e, or SaCas9-ABE8e.

### Claim 19 (depends on 15)

The composition of claim 15, wherein the base editor comprises Cas9 endonuclease.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the Cas9 endonuclease comprises Type II Cas9.
